Comprehensive management of nonmelanoma skin cancer involving the skull base
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Citação
CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, v.30, n.2, p.119-124, 2022
Resumo
Purpose of review Skin cancers are the most prevalent malignant disorder affecting humans. Approximately 90% of these are nonmelanoma skin cancer (NMSC), and large tumors, especially at the 'H-zone', can invade deeply and access the skull base. The best treatment for these very advanced skin cancers is craniofacial resection followed by adjuvant treatment, but, currently, systemic therapy and neoadjuvant approaches could be considered for some patients. The current management of NMSC involving the skull base is discussed in this article. Recent findings Surgical resections with negative margins followed by adjuvant treatment are the best treatment for NMSC with skull base invasion and offer the best outcomes for those patients. This approach usually requires a free flap reconstruction, followed by external beam radiation therapy. The team must keep in mind that some factors, such as gross brain invasion and extensive dura mater extension, are associated with worse outcomes. Although it occurs infrequently, very advanced NMSC can involve the skull base. In these very difficult clinical scenarios, the best therapeutic option is a multidisciplinary approach in a tertiary center.
Palavras-chave
head and neck neoplasms, skin neoplasms, skull base, surgery, treatment outcome
Referências
- Ally MS, 2014, J AM ACAD DERMATOL, V71, P904, DOI 10.1016/j.jaad.2014.05.020
- Balamucki CJ, 2015, AM J CLIN ONCOL-CANC, V38, P248, DOI 10.1097/COC.0b013e3182940ddf
- Balamucki CJ, 2012, AM J OTOLARYNG, V33, P447, DOI 10.1016/j.amjoto.2011.11.004
- Cakir BO, 2012, FACIAL PLAST SURG CL, V20, P419, DOI 10.1016/j.fsc.2012.07.004
- Cannon RB, 2017, OTOLARYNG HEAD NECK, V156, P671, DOI 10.1177/0194599817691923
- Cernea CR, 1997, ANN OTO RHINOL LARYN, V106, P927, DOI 10.1177/000348949710601108
- Clayman GL, 2005, J CLIN ONCOL, V23, P759, DOI 10.1200/JCO.2005.02.155
- Danhof R, 2018, AM J CLIN DERMATOL, V19, P195, DOI 10.1007/s40257-017-0319-4
- Santos ABD, 2017, BRAZ J OTORHINOLAR, V83, P94, DOI 10.1016/j.bjorl.2016.01.009
- Dias FL, 1997, ARCH OTOLARYNGOL, V123, P738
- Donald PJ, 2011, SKULL BASE-INTERD AP, V21, P343, DOI 10.1055/s-0031-1284216
- Dundar Y, 2017, J NEUROL SURG PART B, V78, P164, DOI 10.1055/s-0036-1594239
- Harris BN, 2017, OTOLARYNG HEAD NECK, V156, P863, DOI 10.1177/0194599817697053
- Jackson JE, 2009, HEAD NECK-J SCI SPEC, V31, P604, DOI 10.1002/hed.20991
- LAWRENCE N, 1994, J AM ACAD DERMATOL, V31, P30, DOI 10.1016/S0190-9622(94)70131-8
- Leite AKN, 2021, CLINICS, V76, DOI 10.6061/clinics/2021/e2836
- Maghami EG, 2007, HEAD NECK-J SCI SPEC, V29, P1136, DOI 10.1002/hed.20656
- Nakamura R, 2020, J NEUROL SURG PART B, V81, P121, DOI 10.1055/s-0038-1676777
- Panizza B, 2012, HEAD NECK-J SCI SPEC, V34, P1622, DOI 10.1002/hed.21986
- Patel SG, 2003, CANCER, V98, P1179, DOI 10.1002/cncr.11630
- Raza SM, 2015, J NEUROSURG, V123, P781, DOI 10.3171/2014.10.JNS141037